Economic impact of drug-eluting stents on hospital systems: a disease-state model.

[1]  D. Mark,et al.  Medical economics and the assessment of value in cardiovascular medicine: Part I. , 2002, Circulation.

[2]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[3]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[4]  E Regar,et al.  Stent development and local drug delivery. , 2001, British medical bulletin.

[5]  J. Kahn,et al.  Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. , 2001, American Journal of Public Health.

[6]  A. Coats.  Making choices in cardiology: difficulties of rationing and equality of access. , 2001, International journal of cardiology.

[7]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[8]  L. Goldman,et al.  Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction , 2000 .

[9]  S. Mattke.  Cardiology and cost control: the ethical challenge for the new millennium , 2000, Zeitschrift für Kardiologie.

[10]  D. Kong.  Steroids for restenosis: strike three! , 1999, American heart journal.

[11]  D. Cohen,et al.  Evaluation of the cost-effectiveness of coronary stenting: A societal perspective ☆ ☆☆ ★ ★★ , 1999 .

[12]  E. DeLong,et al.  Acute and long-term cost implications of coronary stenting. , 1999, Journal of the American College of Cardiology.

[13]  P. Amouyel,et al.  Predictors of restenosis after coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[14]  D. Cohen,et al.  Cost-effectiveness of coronary interventions , 1997, Heart.

[15]  M. Hadamitzky,et al.  Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. , 1997, Circulation.

[16]  T. Iwama,et al.  Repeat coronary angioplasty as the treatment of choice for restenosis. , 1996, American heart journal.

[17]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[18]  C. J. Rosenquist,et al.  The use of low-osmolar contrast agents: technological change and defensive medicine. , 1996, Journal of health politics, policy and law.

[19]  C. Kjellstrand.  High‐technology medicine and the old: the dialysis example , 1996, Journal of internal medicine.

[20]  L. Briceland,et al.  Survey of Antibiotic Control Policies in University-Affiliated Teaching Institutions , 1996, The Annals of pharmacotherapy.

[21]  M. Leon,et al.  Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.

[22]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[23]  L. Goldman,et al.  Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. , 1994, Circulation.

[24]  P. Hofschire,et al.  Hidden problems in current health-care financing and potential changes. , 1993, The American psychologist.

[25]  L. Goldman,et al.  Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. , 1991, JAMA.